- Home
- HRMY vs SPNT Comparison
HRMY vs SPNT Comparison
Compare HRMY & SPNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HRMY | SPNT |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.3B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRMY | SPNT |
|---|---|---|
| Price | $36.78 | $19.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $49.75 | $24.00 |
| AVG Volume (30 Days) | ★ 615.1K | 562.9K |
| Earning Date | 02-24-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.44 | N/A |
| EPS | ★ 3.17 | 1.45 |
| Revenue | $825,944,000.00 | ★ $2,859,100,000.00 |
| Revenue This Year | $23.29 | $0.89 |
| Revenue Next Year | $15.98 | $6.87 |
| P/E Ratio | ★ $11.58 | $13.77 |
| Revenue Growth | ★ 21.13 | 6.92 |
| 52 Week Low | $25.52 | $13.26 |
| 52 Week High | $40.93 | $22.89 |
Technical Indicators
Market Signals| Indicator | HRMY | SPNT |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 39.25 |
| Support Level | $35.16 | $19.62 |
| Resistance Level | $37.08 | $20.22 |
| Average True Range (ATR) | 1.43 | 0.59 |
| MACD | -0.21 | -0.13 |
| Stochastic Oscillator | 43.22 | 16.19 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About SPNT SiriusPoint Ltd.
SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.